Mobile
Recherche simple
Recherche avancée
Recherche multicritère
Qui sommes-nous ?
Connexion
Inscription
French
English
Kusajili – Centralise les essais cliniques mondiaux
Résultat
de votre recherche par promoteur : Eisai
Femme et Homme Max 99 ans
Eisai Limited
MAJ Il y a 4 ans
A Randomised, Double-Blind, Placebo-Controlled Study of the Safety and Tolerability of E5555, and its Effects on Clinical Events and Biomarkers in Patients with Non-ST-Segment Elevation Acute Coronary Syndrome
The primary objectives of the study are to investigate the safety and tolerability of E5555 at three dose levels in patients admitted to hospital with symptoms of ACS. This will be assessed for a peri...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme
Entre 65 ans
et 99 ans
Eisai Medical Research Inc.
MAJ Il y a 4 ans
EISAI DACO-016 : Essai de phase 3 randomisé comparant l’efficacité un traitement par décitabine à un traitement symptomatique ou par de faible dose de cytarabine chez des patients âgés ayant une leucémie aigüe myéloïde. [Informations issues du site clinicaltrials.gov et traduites par l'INCa] [essai clos aux inclusions]
Randomized phase 3 trial of decitabine versus patient's choice with physician's advice of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute m...
Pays
France
Organes
Leucémies aiguës
Spécialités
Chimiothérapie
,
Gériatrie
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Eisai Limited
MAJ Il y a 4 ans
A Multi-centre, Open Label Extension Study to Evaluate the Long-term Safety, Tolerability and Efficacy of E2007 as an Adjunctive Therapy in Levodopa Treated Parkinson's Disease Patients with Motor Fluctuations
To evaluate the long-term safety and tolerability of E2007 as an adjunctive therapy in levodopa treated Parkinson’s disease (PD) patients with motor fluctuations.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Eisai Limited
MAJ Il y a 4 ans
A randomized, double-blind extension study to assess the long-term safety and to explore the long term efficacy of zonisamide as monotherapy in newly diagnosed partial seizures. Estudio de extensión aleatorizado, doble ciego, para evaluar la seguridad a largo plazo y examinar la eficacia a largo plazo de zonisamida como monoterapia en pacientes con epilepsia parcial recién diagnosticada
To assess the long-term safety and to explore the long-term efficacy of zonisamide when given as monotherapy to newly diagnosed subjects with partial seizures.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme Max 99 ans
Eisai Limited
MAJ Il y a 4 ans
A Randomized, Double-blind, Placebo-Controlled, Phase 3 Study to Assess the Efficacy and Safety of Weekly Farletuzumab (MORAb-003) in Combination with Carboplatin and Taxane in Subjects with Platinum-sensitive Ovarian Cancer in First Relapse
To assess the effect of two dose levels of MORAb-003 or placebo in combination with carboplatin and taxane on progression-free survival (PFS), as determined by RECIST, in subjects with platinum-sensit...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Eisai Ltd
MAJ Il y a 4 ans
A Clinical Trial comparing the Efficacy and Safety of Eribulin and a Treatment of the Doctor's Choice in Patients with Non-Small Cell Lung Cancer. ENSAYO CLÍNICO QUE COMPARA LA EFICACIA Y LA SEGURIDAD DE ERIBULINA Y UN TRATAMIENTO ELEGIDO POR EL MÉDICO EN PACIENTES CON CÁNCER DE PULMÓN NO MICROCÍTICO
To compare overall survival (OS) in subjects with advanced non-small cell lung cancer (NSCLC) when treated with eribulin (Arm A) and treatment of physician?s choice ([TPC] Arm B). Comparar la su...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Eisai Limited
MAJ Il y a 4 ans
A research study to find out if people with Primary Generalized Tonic-Clonic Seizures, by taking perampanel in addition to their normal epilepsy medicine(s), have fewer seizures and feel better. Either perampanel (real medicine) or placebo (pretend medicine that looks the same as the real medicine) will be given in addition to ordinary epilepsy medicines. Who gets which is decided randomly. There is an option to continue into the Follow-on (Extension) Phase of the study
To demonstrate the efficacy of adjunctive perampanel therapy, compared to placebo, on primary generalized tonic-clonic (PGTC) seizures
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Eisai Ltd
MAJ Il y a 4 ans
A Clinical Trial Comparing the Effectiveness and Safety of Eribulin and Dacarbazine for Treatment of Patients with Soft Tissue Sarcoma (A Type of Cancer)" "Un ensayo clínico que compara la eficacia y la seguridad de eribulina y dacarbazina en el tratamiento de pacientes con sarcoma de tejidos blandos (un tipo de cáncer)
To compare overall survival (OS) in subjects with advanced soft tissue sarcoma ([STS], one of two subtypes: adipocytic [ADI] or leiomyosarcoma [LMS]) when treated with eribulin (Arm A) or dacarbazine ...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Eisai Ltd
MAJ Il y a 4 ans
A Double-Blind, Placebo-Controlled, Dose-Escalation, Parallel-Group Study to Evaluate the Efficacy and Safety of E2007 (perampanel) Given as Adjunctive Therapy in Subjects with Refractory Partial Seizures
The primary objective is to evaluate the efficacy of 2 doses of perampanel (8 and 12 mg) in comparison to placebo given as an adjunctive therapy in subjects with refractory partial seizures.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Eisai Limited
MAJ Il y a 4 ans
Randomized, Double-Blind, Placebo-Controlled Study of Efficacy and Safety of Donepezil Hydrochloride in Preadolescent and Adolescent Children with Attention Impairment Following Cancer Treatment
To evaluate the efficacy of donepezil in children with attention impairment that is present at least 12 months after the completion of cancer treatment
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Précédent
3
4
5
6
7
8
9
Suivant